The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027.
Last week, the Biden administration announced that Medicare's newly negotiated prescription drug prices are expected to save the U.S. government $6 billion in the first year alone.
According to some analysts, Novo Nordisk A/S' (NYSE:NVO) blockbuster diabetes drug Ozempic might be included, along with several other well-known medications.
Also Read: Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy.
These could include Pfizer Inc.'s (NYSE:PFE) cancer drugs Ibrance and Xtandi, GSK Plc's (NYSE:GSK) asthma treatment Trelegy Ellipta, Teva Pharmaceutical Industries Ltd.'s (NYSE:
